Open an account

Innoveren Scientific

IVRN · OTC

$0.0003+$0.0001 (+50.00%)TodayMarket closed ·
No price history for this range.

About IVRN

Innoveren Scientific, Inc. is a hybrid-biopharmaceutical company. The company is headquartered in Cincinnati, Ohio. The company went IPO on 2014-12-19. The firm is focused on advancing technologies in areas of unmet need across multiple indications for improving patient lives. Its product pipeline includes SkinDisc Lite, SkinDisc, and BreathEasy. From a single application, SkinDisc provides an active cellular matrix that maintains complete full wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. The SkinDisc product achieves healing in four to nine weeks. BreatheEasy is a 510(k) De Novo pathway medical device that is an autologous IV infusion that helps patients struggling with COPD, as well as other closely related diseases, such as chronic bronchitis and emphysema.

Employees
26
Headquarters
Cincinnati, Ohio
Listed
Dec 19, 2014
Sector
Health Care
Industry
Biotechnology
Website
hcyte.com

IVRN key statistics

Market cap
2.40K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
269
Volume
1
Open price
$0.0003
High today
$0.0003
Low today
$0.0003
52 Week high
$0.0007
52 Week low
$0.00

Innoveren Scientific (IVRN) at a glance

Innoveren Scientific (IVRN) last traded at $0.0003, with a market cap of 2.40K and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 269 shares a day.

Over the past year Innoveren Scientific has ranged from $0.00 to $0.0007, and now sits 43% of the way up that range.

Innoveren Scientific met or beat analyst EPS estimates in 4 of the last 4 quarters. In Q3 FY23 it reported $0.77 per share against an estimate of $0.00.

IVRN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 4 quarters, by 30.7% on average.

  1. Q2 FY17: reported -$70.00 per share against an estimate of -$163.20
  2. Q3 FY17: reported -$70.00 per share against an estimate of -$204.00
  3. Q2 FY23: reported $0.77 per share against an estimate of $0.00
  4. Q3 FY23: reported $0.77 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Innoveren Scientific

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.